

Futura Medical
Advanced Transdermal Technology

Investor fact sheet

May 2017

Futura Medical plc

Surrey Technology Centre
40 Occam Road
The Surrey Research Park
Guildford, Surrey, GU2 7YG

Tel: 01483 685670
info@futuramedical.com
www.futuramedical.com

Management

Chairman

John Clarke - Extensive experience of the Healthcare sector having worked at GSK for more than 35 years.

Chief Executive

James Barder - Over 25 years of experience in setting up, managing and running companies.

Executive Director -Head of R&D

Ken James - Over 40 years' experience in research and development.

Finance Director

Derek Martin - Over 25 years' experience in finance.

Non Executive Director

Jonathan Freeman - Over 25 years' experience in the financial services sector, guidance on City regulatory matters, corporate finance and investor relations.

Share statistics

(as at close 2 May 2017)

Share price: 51.25p
Shares in issue (m): 120.63
Market cap (£m): 61.82
Year end: 31 December

Sector: Pharmaceuticals
Activities: Advanced transdermal technology
Broker/NOMAD: N+1 Singer



What we do

Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using its advanced proprietary transdermal technology, DermaSys[®]. We have five products in our development pipeline for sexual healthcare and pain relief. We continue to evaluate further product opportunities utilising our DermaSys[®] technology.

Strategy

- **Advanced Transdermal Technology:** Offering innovative delivery of proven compounds through the skin to improve their performance or to address new indications.
- **Controlled Development Risk:** Using only approved compounds to control the risk profile.
- **Strong Intellectual Property:** Developing products where the Group can secure strong patent protection.
- **Commercialisation:** Out-licensing products to leading healthcare companies which offer the optimum potential financial return.

Commercial Partnerships

Futura has several agreements with leading pharmaceutical and healthcare groups for the distribution of its product CSD500 and has recently signed its first agreement for the distribution of TPR100.

DermaSys[®] Technology

Futura has developed a highly efficient and proprietary delivery technology, DermaSys[®], for the absorption of active molecules through the skin. DermaSys[®] is a versatile and bespoke technology in that it can be tailored to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects.

Major shareholders - May 2017

Lombard Odier Asset Mgmt	19.3%	WT Lamb Investments	3.9%
Octopus Asset Mgmt	7.9%	Medinvest	3.5%
RA Lamb	7.9%		

Key financial data

	Year ended 31 Dec 16 (£'000)	Year ended 31 Dec 15 (£'000)	Year ended 31 Dec 14 (£'000)
Revenue/Income	170	29	44
R&D	(3,510)	(4,778)	(2,366)
Other administrative costs	(1,215)	(1,368)	(1,205)
Operating loss	(4,554)	(6,117)	(3,527)
Finance income	15	38	48
Tax credit receivable	842	997	481
Loss after tax	(3,697)	(5,081)	(2,998)
Net cash	12,353	4,188	9,492

Recent significant news flow


- 23 Mar 17 Preliminary Results for 2016
- 22 Mar 17 Licenses CSD500 in Portugal
- 06 Mar 17 Research Confirms MED2002's US\$1 Billion Potential
- 06 Mar 17 MED2002 Additional Patent Filing
- 10 Jan 17 Futura signs UK Licensing Agreement in Pain Relief
- 05 Jan 17 Initial Launch of CSD500 in MENA

6 month share price performance




Our Pipeline

Sexual Healthcare



Pain Relief



Investor Relations Contacts

Buchanan Communications

Mark Court
mark@buchanan.uk.com
Telephone: +44 (0)20 7466 5000

Futura Medical plc

James Barder, Chief Executive
james.barder@futura-medical.com
Telephone: +44 (0)1483 685 670

